Cargando…
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
Currently the 21-gene recurrence score (RS) assay called Oncotype DX is recommended by the National Comprehensive Cancer Network guideline for defining the benefit of chemotherapy. To overcome the cost disadvantages of the Oncotype DX assay and the turnaround time, a multigene assay was examined to...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341800/ https://www.ncbi.nlm.nih.gov/pubmed/30675242 http://dx.doi.org/10.3892/ol.2018.9784 |